• Vetiranary Medicine
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Practical Matters: Consider immunohistochemistry when identifying tumors

March 1, 2005
Kevin A. Hahn, DVM, PhD, DACVIM (oncology)

Comparing the microscopic features of tumor cells with their normal cellular counterparts is the key to diagnosing a neoplastic disease.

Comparing the microscopic features of tumor cells with their normal cellular counterparts is the key to diagnosing a neoplastic disease. Thus, cellular identification is frequently achieved with well-differentiated tumors; however, assigning a cell of origin in a poorly differentiated tumor is difficult. Identifying the tissue of origin in an undifferentiated tumor is important in determining the patient's prognosis and planning the treatment.

Laboratories have access to hundreds of antibodies for immunohistochemical testing. (Veterinary laboratories are preferred because human immunohistochemical tests may not be useful for animal tissue.) Some antibodies only react with one type of cancer, but other antibodies react with several types, so testing with several different antibodies helps determine the cancer's origin. Most procedures may be performed on formalin-fixed tissues; however, fresh or frozen tissue samples prepared on unstained slides may be necessary for others.

Epithelial tissue and tumors of epithelial origin (carcinomas) stain positive for various cytokeratin filaments. Neural filaments are diagnostic of neural cells and some neuroendocrine tumors. Vimentin, an intermediate filament, is typically present in mesenchymal cells and their derived tumors, such as sarcomas and other nonepithelial neoplasms. Desmin, an intermediate filament, is characteristically present in muscle cells and most tumors derived from muscle cells. Kappa and lambda light chains are excellent markers for canine B cell lymphomas and plasmacytomas. Neuron-specific enolase and S-100 protein are often present within amelanotic melanomas. The combined use of vimentin, S-100 protein, and neuron-specific enolase helps distinguish amelanotic melanoma from other undifferentiated round cell tumors in dogs. CD18 can detect all bone-marrow-derived cells, while CD3 will stain T cells, and CD79a will mark B cells. Other connective tissue sarcomas can be identified by the presence of smooth muscle actin, desmin, factor VIII-related antigen, and glial fibrillary acidic protein. Carcinomas can be further characterized by staining for specific proteins, such as various hormones and hormone receptors (e.g. an estrogen receptor). Consultation with a veterinary pathologist regarding the selection of an appropriate stain or with a veterinary oncologist before tissue submission can be helpful.

Advertisement

By considering the immunohistochemical test results in the context of the tumor's appearance after a routine histologic examination, the location of the tumor's metastasis, and other information such as the patient's age and sex, it is often possible to find the source of the cancer or to classify the cancer in a way that helps guide treatment.

Kevin A. Hahn, DVM, PhD, DACVIM (oncology)

Gulf Coast Veterinary Specialists

1111 West Loop South, Suite 150

Houston, TX 77027

Related Content:

Oncology
3 categories of inappetence in dogs
3 categories of inappetence in dogs
Feline oral cancer is the focus of a new study
Feline oral cancer is the focus of a new study
Advances in the detection, characterization, and monitoring of cancer in pets
Advances in the detection, characterization, and monitoring of cancer in pets

Advertisement

Latest News

How to support women while still running a successful business

The Vets expands to Raleigh, NC

Two pups find their forever homes while at Fetch Charlotte

Tools for building a growth mindset

View More Latest News
Advertisement